TB-500 (Thymosin Beta-4): A Research Overview of an Actin-Sequestering Peptide

TB-500 is a synthetic research peptide based on the 17-amino-acid active sequence of thymosin beta-4, a small actin-sequestering protein originally isolated from calf thymus in the early 1980s. The full-length parent molecule, thymosin beta-4, is the most abundant member of the beta-thymosin family and the most abundant G-actin-binding peptide in mammalian cells. The TB-500 research-peptide form is the soluble fragment containing the central actin-binding motif (the LKKTETQ sequence) used in laboratory research on cytoskeletal biology, cell migration, and tissue-repair signaling.

This article is a research-context overview of TB-500: its biochemistry, the published animal-research literature on its proposed mechanisms, and the practical handling notes that matter for in-lab use. Where the published literature is explicit, it is cited; where the literature is sparse, the gaps are noted rather than filled with speculation.

Identity and biochemistry

The full-length thymosin beta-4 sequence is a 43-amino-acid acidic peptide. The molecule is unstructured in solution but adopts an alpha-helical conformation when bound to G-actin. The CAS registry number for the full-length molecule is 77591-33-4; its molecular weight is approximately 4963 Da and its empirical formula is C₂₁₂H₃₅₀N₅₆O₇₈S.

TB-500 (the research peptide) is sold under that trade name to mean the central actin-binding 17-amino-acid fragment containing the LKKTETQ motif and flanking residues. The fragment carries the actin-binding activity of the full molecule and is the form most commonly used in research applications. Some vendors also use the term “TB-500” to refer to the full-length 43-amino-acid thymosin beta-4; readers of any vendor’s CoA should confirm which form is in the vial by checking the molecular weight reported.

The published literature uses “thymosin beta-4” (Tβ4) and “TB-500” interchangeably in many places; this article uses “thymosin beta-4” when citing the original biology and “TB-500” when discussing the research-peptide form.

The actin-sequestering mechanism

The defining biochemical activity of thymosin beta-4 is binding to monomeric G-actin in a 1:1 complex, thereby sequestering the monomer and preventing its incorporation into F-actin filaments. The crystal structure of the thymosin beta-4 / G-actin complex was solved in the early 2000s and confirmed the binding mode predicted by sequence-conservation analysis. The actin-binding site of the peptide is centered on the LKKTETQ motif, which folds into a short alpha-helix on the actin surface.

The biological consequence of this sequestering activity is regulation of the cytoplasmic G-actin pool, which in turn regulates the rate and direction of cytoskeletal polymerization required for cell-shape changes, lamellipodial protrusion, and directional cell migration. In motile cells (fibroblasts, endothelial cells, leukocytes), thymosin beta-4 is one of several proteins that buffer the G-actin pool and contribute to the kinetics of actin-treadmilling.

A second category of reported activity is non-canonical signaling. Published cell-culture and animal-research work has reported that exogenous thymosin beta-4 can upregulate the Akt/protein kinase B pathway, modulate the expression of laminin-5 in re-epithelializing tissue, and influence the expression of integrins on migrating cells. These reports are summarized in Goldstein AL, Hannappel E, Sosne G, Kleinman HK, “Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications,” Expert Opinion on Biological Therapy 12(1):37–51, 2012 (DOI: 10.1517/14712598.2012.634793), which remains a commonly-cited review of the regenerative-biology research.

Published animal-research findings

The published animal-research literature on thymosin beta-4 spans several tissue-repair model systems. Reported findings, summarized from peer-reviewed publications, include:

Cutaneous wound-healing models — animal full-thickness wound studies have reported accelerated re-epithelialization, increased angiogenesis at the wound margin, and decreased inflammatory infiltrate following exogenous thymosin beta-4 administration. The original characterization by Malinda KM, et al., “Thymosin beta 4 accelerates wound healing,” Journal of Investigative Dermatology 113(3):364–368, 1999 (DOI: 10.1046/j.1523-1747.1999.00708.x), is widely cited as a foundational result.
Corneal repair models — animal studies have reported improved corneal re-epithelialization in models of chemical and mechanical injury. Sosne G, et al., “Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury,” Experimental Eye Research 74(2):293–299, 2002 (DOI: 10.1006/exer.2001.1125), describes the model system most often cited in this area.
Cardiac tissue-injury models — published work has reported pro-survival and pro-angiogenic effects in animal models of cardiac injury. Bock-Marquette I, et al., “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair,” Nature 432(7016):466–472, 2004 (DOI: 10.1038/nature03000), is the most-cited reference for the cardiac-biology research.

These are animal-model findings. The clinical-trial data in humans is limited; thymosin beta-4 has been the subject of small-scale exploratory clinical research, but no approved human-use indication exists.

Where TB-500 fits in a research-compound catalog

TB-500 is typically grouped with BPC-157 in research-compound catalogs under the broad “tissue-repair research” heading. The two peptides have non-overlapping characterized mechanisms — BPC-157 acts upstream on growth-factor and nitric-oxide signaling pathways, while TB-500 acts on the cytoskeletal actin-pool regulation pathway — and are sometimes studied in parallel or as a combined-peptide research preparation. Combined BPC-157 + TB-500 preparations are available from research-supply vendors as a research-blend option; the stand-alone TB-500 vial is for research using thymosin beta-4 alone.

Solubility, reconstitution, and storage

TB-500 is supplied as a lyophilized powder. The recommended reconstitution solvent for research use is sterile bacteriostatic water (BAC water, sterile water containing 0.9% benzyl alcohol as a bacteriostatic agent). Sterile saline is an acceptable alternative for short-term research use. The reconstituted peptide should be aliquoted before freezing to avoid repeated freeze-thaw cycles, which can cause loss of bioactivity through aggregation or partial denaturation.

Specific storage protocols:

Lyophilized vial (unopened): -20°C, protected from light, dry. Stable for 1-2+ years under these conditions when properly sealed.
Reconstituted (short-term): 2-8°C in the original reconstituted vial. Typical short-term stability is 2-4 weeks in refrigerated solution; vendor-specific stability data should be consulted on the CoA.
Reconstituted (long-term): aliquot into single-use volumes, freeze at -20°C or -80°C, thaw once just before use.

For the full reconstitution-and-storage protocol, see guide on lyophilized vs. reconstituted peptide storage.

Reading a TB-500 CoA

A research-grade TB-500 CoA should document the same fields as any peptide CoA: lot number, manufacturing date, HPLC purity (≥99.0% expected for a research-grade preparation), mass spectrometry identity confirmation (observed mass within ±0.5 Da of theoretical), and net peptide content with the counterion identified. The molecular weight on the CoA should match the form being sold: ~1898 Da for the 17-amino-acid fragment, or ~4963 Da for the full-length 43-amino-acid molecule. A vendor’s CoA that does not specify which form is in the vial is incomplete.

For a step-by-step guide on reading a peptide CoA, see article on how to read a peptide Certificate of Analysis.

What the published literature does not establish

It is worth being explicit about the limits of the research literature on TB-500 and thymosin beta-4. The published evidence comprises predominantly animal-model and cell-culture studies; the human-clinical trial literature is limited and consists mostly of small exploratory studies. The mechanistic literature is strongest on the actin-sequestering function, where the structure-function relationship is directly characterized; it is weaker on the secondary signaling effects (Akt, laminin-5, integrins), where the molecular mediators are less precisely defined.

The peptide has no approved therapeutic indication in any jurisdiction. Vials sold for research use are intended for in-vitro experimentation and animal-research investigations under appropriate institutional oversight. Any extrapolation from the animal-study findings to human use is not supported by the regulatory science.

Summary

TB-500 is a synthetic research peptide based on the central actin-binding fragment of thymosin beta-4, an abundant mammalian G-actin-sequestering peptide. The characterized mechanism is cytoskeletal regulation via 1:1 G-actin binding, with additional reported activity on the Akt pathway and on integrin / laminin expression. Published animal-research findings span cutaneous wound healing, corneal repair, and cardiac injury models, with the regenerative-biology literature reviewed by Goldstein and colleagues. The peptide is supplied lyophilized and is stored frozen for long-term stability; reconstitution should use sterile bacteriostatic water and should avoid freeze-thaw cycles. A research-grade CoA documents purity, identity, and net peptide content for the lot.

For the companion compound, see the BPC-157 research overview.

Research Use Only — Disclaimer

The research peptides discussed on this page are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and for use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption, not for veterinary use in companion animals, and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing on this page constitutes medical advice. No statement on this page should be interpreted as a recommendation, claim, or representation that any peptide compound is safe, effective, or appropriate for any use in humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.